NCT06138249 Cholecalciferol and Calcifediol Are Both Useful to Improve Vitamin D Serum Levels
| NCT ID | NCT06138249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari |
| Condition | Hypovitaminosis D |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-07-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with hypovitaminosis D are randomized into three arms of treatment: Group A: Calcifediol 0,266mg each month Group B: Cholecalciferol 25000UI each 15 days Group C: Calcifediol 4 drops per day. Serum levels of vitamin D are dosed after one month of treatment
Eligibility Criteria
Inclusion Criteria: * Hypovitaminosis D (\<20ng/mL) Exclusion Criteria: * Osteoporosis (T score \<-2.5SD) * Renal or hepatic diseases
Contact & Investigator
Angela Notarnicola, AP
STUDY CHAIR
University of Bari
Frequently Asked Questions
Who can join the NCT06138249 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypovitaminosis D. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06138249 currently recruiting?
Yes, NCT06138249 is actively recruiting participants. Contact the research team at silvana.degiorgi@uniba.it for enrollment information.
Where is the NCT06138249 trial being conducted?
This trial is being conducted at Bari, Italy.
Who is sponsoring the NCT06138249 clinical trial?
NCT06138249 is sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. The principal investigator is Angela Notarnicola, AP at University of Bari. The trial plans to enroll 90 participants.